TERN News and Press, Terns Pharmaceuticals Inc.

2024-07-17 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...

FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including on...

2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...

FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including on...

2024-05-13 08:45:24 ET More on Terns Pharmaceuticals Terns Pharmaceuticals releases promising phase 1 data on leukemia candidate Terns Pharmaceuticals appoints Melita Sun Jung as chief business officer Seeking Alpha’s Quant Rating on Terns Pharmaceuticals ...

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in 2H24 Cash, cash equivalents and marketable securities of $241 ...

2024-05-10 15:00:11 ET More on the markets SPY: Growing Signs The Market Is Overbought SPY: The Shrinking Market For U.S. Companies SPY: Stronger Than Ever For the second consecutive week, investors purchase ETFs and conventional funds Earnings estima...

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...